ES2537777T3 - Composiciones farmacéuticas para inhalación en forma de polvos secos, soluciones o suspensiones - Google Patents
Composiciones farmacéuticas para inhalación en forma de polvos secos, soluciones o suspensiones Download PDFInfo
- Publication number
- ES2537777T3 ES2537777T3 ES06807435.0T ES06807435T ES2537777T3 ES 2537777 T3 ES2537777 T3 ES 2537777T3 ES 06807435 T ES06807435 T ES 06807435T ES 2537777 T3 ES2537777 T3 ES 2537777T3
- Authority
- ES
- Spain
- Prior art keywords
- tween
- lactose
- budesonide
- solids
- conc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000243 solution Substances 0.000 title description 2
- 239000000725 suspension Substances 0.000 title description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 49
- 239000002245 particle Substances 0.000 abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 29
- 239000007787 solid Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 18
- 239000004094 surface-active agent Substances 0.000 abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 48
- 239000008101 lactose Substances 0.000 description 48
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 46
- 229920000053 polysorbate 80 Polymers 0.000 description 46
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 32
- 229960004436 budesonide Drugs 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000001694 spray drying Methods 0.000 description 28
- 239000002904 solvent Substances 0.000 description 26
- 239000007921 spray Substances 0.000 description 26
- 239000004395 L-leucine Substances 0.000 description 24
- 235000019454 L-leucine Nutrition 0.000 description 24
- 229960003136 leucine Drugs 0.000 description 24
- 229960000484 ceftazidime Drugs 0.000 description 19
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 11
- 229960000193 formoterol fumarate Drugs 0.000 description 11
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 10
- 229960002848 formoterol Drugs 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 239000006199 nebulizer Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010078777 Colistin Proteins 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20051999 | 2005-10-21 | ||
| ITMI20051999 ITMI20051999A1 (it) | 2005-10-21 | 2005-10-21 | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| PCT/EP2006/067619 WO2007045689A2 (en) | 2005-10-21 | 2006-10-20 | Inhalatory pharmaceutical compositions in form of dry powders, solutions or suspensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2537777T3 true ES2537777T3 (es) | 2015-06-12 |
Family
ID=37806135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06807435.0T Active ES2537777T3 (es) | 2005-10-21 | 2006-10-20 | Composiciones farmacéuticas para inhalación en forma de polvos secos, soluciones o suspensiones |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9138407B2 (enExample) |
| EP (1) | EP1937229B1 (enExample) |
| JP (1) | JP5873616B2 (enExample) |
| CY (1) | CY1116503T1 (enExample) |
| DK (1) | DK1937229T3 (enExample) |
| ES (1) | ES2537777T3 (enExample) |
| HU (1) | HUE026045T2 (enExample) |
| IT (1) | ITMI20051999A1 (enExample) |
| PL (1) | PL1937229T3 (enExample) |
| PT (1) | PT1937229E (enExample) |
| RU (1) | RU2497507C2 (enExample) |
| SI (1) | SI1937229T1 (enExample) |
| WO (1) | WO2007045689A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US6923175B2 (en) | 2002-03-20 | 2005-08-02 | Mannkind Corporation | Inhalation apparatus |
| CN101010305B (zh) | 2004-08-20 | 2010-08-11 | 曼金德公司 | 二酮哌嗪合成的催化反应 |
| BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
| KR101384456B1 (ko) | 2005-09-14 | 2014-04-10 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| AU2006335994A1 (en) | 2006-01-19 | 2007-07-26 | Optinose As | Nasal administration |
| ES2647080T3 (es) | 2006-02-22 | 2017-12-19 | Mannkind Corporation | Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo |
| US8614236B2 (en) * | 2006-12-12 | 2013-12-24 | University Of Washington | Methods of treating pulmonary disease using acetazolamide and structurally related derivatives |
| GB2448183A (en) | 2007-04-05 | 2008-10-08 | Optinose As | Nasal powder delivery device |
| WO2011163272A1 (en) | 2010-06-21 | 2011-12-29 | Mannkind Corporation | Dry powder drug delivery system and methods |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| LT3354276T (lt) | 2007-11-13 | 2020-04-27 | Meritage Pharma, Inc. | Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui |
| US9050368B2 (en) * | 2007-11-13 | 2015-06-09 | Meritage Pharma, Inc. | Corticosteroid compositions |
| JP5570996B2 (ja) | 2007-12-14 | 2014-08-13 | エアロデザインズ インコーポレイテッド | エアロゾル化可能な食料品の送達 |
| JP5485879B2 (ja) * | 2008-05-15 | 2014-05-07 | 株式会社ココカラファインネクスト | 異なる物性の薬物の一剤形化 |
| DK2293833T3 (en) | 2008-06-13 | 2016-05-23 | Mannkind Corp | DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CA2728523C (en) | 2008-06-20 | 2020-03-10 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| CA2835771C (en) * | 2009-03-18 | 2017-01-24 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| US8551528B2 (en) | 2009-06-12 | 2013-10-08 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| RU2445119C2 (ru) * | 2010-05-25 | 2012-03-20 | Сергей Викторович Чепур | Фармацевтическая композиция и способ ее ингаляционного введения |
| CN107096014B (zh) | 2010-09-29 | 2022-07-15 | 普马特里克斯营业公司 | 吸入用单价金属阳离子干粉剂 |
| GB2488992A (en) * | 2011-03-10 | 2012-09-19 | Advanced Ophthalmic Pharma Ltd | Medicament dispenser |
| ES2625858T3 (es) | 2011-04-01 | 2017-07-20 | Mannkind Corporation | Paquete de tipo blíster para cartuchos farmacéuticos |
| HRP20161757T1 (hr) * | 2011-05-03 | 2017-02-10 | Chiesi Farmaceutici S.P.A. | Poboljšana formulacija suspenzije beklometazon-dipropionata za davanje inhalacijom |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| CA3098386C (en) | 2012-07-12 | 2022-11-29 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| JP6197515B2 (ja) * | 2012-10-19 | 2017-09-20 | 大正製薬株式会社 | 医薬組成物 |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| KR20180092324A (ko) | 2013-03-13 | 2018-08-20 | 포레스트 래보러토리즈 홀딩스 리미티드 | 미분화된 약제학적 조성물 |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| MX369136B (es) | 2013-03-15 | 2019-10-30 | Mannkind Corp | Composiciones de dicetopiperazina microcristalina y metodos. |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| ITMI20130571A1 (it) * | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| WO2016004409A1 (en) * | 2014-07-03 | 2016-01-07 | Luxena Pharmaceuticals, Inc. | Novel aerosol formulations of ondansetron and uses thereof |
| CN104274426A (zh) | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
| RU2539374C1 (ru) * | 2013-11-29 | 2015-01-20 | Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Высокодисперсная комбинированная фармацевтическая композиция беклометазона и сальбутамола с бета-глицином и способ ее получения |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| CN112656780A (zh) | 2014-02-20 | 2021-04-16 | 奥迪托皮克股份有限公司 | 用于吸入的干粉制剂 |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2015187356A1 (en) * | 2014-06-04 | 2015-12-10 | Quick Joshua Ryan | System and method for delivering an inhalable sugar formulation |
| RU2699995C2 (ru) | 2014-09-15 | 2019-09-12 | ВЕРОНА ФАРМА ПиэЛСи | Жидкая ингаляционная композиция, содержащая rpl 554 |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| KR102462058B1 (ko) | 2014-10-08 | 2022-11-01 | 잠본쏘시에떼퍼아찌오니 | 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물 |
| MX372705B (es) * | 2014-10-08 | 2020-06-18 | Zambon Spa | Composición farmacéutica que contiene budesonida y formoterol |
| CN107106641B (zh) | 2014-10-31 | 2021-12-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 粉末制剂 |
| WO2017022814A1 (ja) * | 2015-08-05 | 2017-02-09 | 第一三共株式会社 | ネブライザー用組成物 |
| EP3346987A1 (en) * | 2015-09-09 | 2018-07-18 | Novartis AG | Targeted delivery of spray-dried formulations to the lungs |
| CN118078742A (zh) | 2015-10-20 | 2024-05-28 | 斯帕方有限公司 | 包含丹曲林的水性组合物 |
| CN109069495A (zh) | 2016-02-01 | 2018-12-21 | 英凯达治疗公司 | 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常 |
| CN109310622A (zh) * | 2016-06-30 | 2019-02-05 | 菲利普莫里斯生产公司 | 尼古丁颗粒和组合物 |
| ES3005760T3 (en) * | 2016-06-30 | 2025-03-17 | Philip Morris Products Sa | Nicotine particles |
| RU2766086C2 (ru) | 2016-10-14 | 2022-02-07 | Пулматрикс Оперэйтинг Компани, Инк. | Противогрибковые сухие порошки |
| RU2770039C2 (ru) * | 2017-03-07 | 2022-04-14 | Филип Моррис Продактс С.А. | Вдыхаемые составы на основе никотина и способы их получения и применения |
| CN110869018A (zh) | 2017-05-10 | 2020-03-06 | 英凯达治疗公司 | 通过肺部施用治疗心脏病况的单位剂量、气雾剂、试剂盒和方法 |
| AU2018318123B2 (en) | 2017-08-15 | 2024-07-25 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| AU2017432640B2 (en) | 2017-09-22 | 2023-11-30 | Aspeya US Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| US11278492B2 (en) | 2018-01-05 | 2022-03-22 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| WO2020150460A1 (en) * | 2019-01-18 | 2020-07-23 | Milne Iii Donald A | Micronized aspirin formulation |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| RU2730488C1 (ru) * | 2019-08-20 | 2020-08-24 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) | Фармацевтическая композиция на основе глюкокортикостероида будесонида и фосфатидилхолина для сухой ингаляции |
| GB201914532D0 (en) * | 2019-10-08 | 2019-11-20 | Univ Of Huddersfield | Lactose particles and method of production thereof |
| RU2735502C1 (ru) * | 2020-01-09 | 2020-11-03 | Федеральное государственное бюджетное учреждение науки Удмуртский федеральный исследовательский центр Уральского отделения Российской академии наук | Аэрозоль для ингаляций при обструктивном бронхите |
| CN111202723A (zh) * | 2020-02-15 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种达芦那韦吸入干粉药物组合物及其制备方法 |
| MX2023001201A (es) * | 2020-07-31 | 2023-05-03 | Chemo Res S L | Terapia combinada para la administracion por inhalacion. |
| US20250108068A1 (en) * | 2023-09-28 | 2025-04-03 | Color Ventures LLC | Compositions and methods for alleviating pulmonary ailments |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3009598B2 (ja) | 1994-02-18 | 2000-02-14 | 武田薬品工業株式会社 | プレフィルドシリンジ |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| DE19636150A1 (de) * | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| WO1999016421A1 (en) | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| JP2002518432A (ja) | 1998-06-24 | 2002-06-25 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 吸入器から放出される大多孔性粒子 |
| EP1210067A2 (en) | 1999-08-25 | 2002-06-05 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| EP1666028B1 (en) | 1999-10-29 | 2010-03-24 | Novartis AG | Dry powder compositions having improved dispersivity |
| GB9929486D0 (en) | 1999-12-15 | 2000-02-09 | Glaxo Group Ltd | Inhalation delivery apparatus and method |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| CA2413692C (en) | 2000-06-27 | 2011-10-18 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US20020103139A1 (en) | 2000-12-01 | 2002-08-01 | M. Weisspapir | Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control |
| US20110123574A1 (en) * | 2002-03-20 | 2011-05-26 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| CA2478974C (en) | 2002-03-20 | 2014-12-16 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
| CA2488976C (en) | 2002-06-28 | 2009-08-25 | Advanced Inhalation Research, Inc. | Inhalable epinephrine |
| EP1556018A1 (en) * | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| JP2006513236A (ja) | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 不溶性活性物質を伴う医薬製剤 |
| EP1617820B1 (en) * | 2003-04-14 | 2018-03-21 | Vectura Limited | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| BRPI0414428A (pt) * | 2003-09-15 | 2006-11-14 | Vectura Ltd | composições farmacêuticas |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US20060292081A1 (en) | 2003-09-15 | 2006-12-28 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
-
2005
- 2005-10-21 IT ITMI20051999 patent/ITMI20051999A1/it unknown
-
2006
- 2006-10-20 DK DK06807435.0T patent/DK1937229T3/da active
- 2006-10-20 US US12/090,899 patent/US9138407B2/en active Active
- 2006-10-20 PL PL06807435T patent/PL1937229T3/pl unknown
- 2006-10-20 ES ES06807435.0T patent/ES2537777T3/es active Active
- 2006-10-20 PT PT68074350T patent/PT1937229E/pt unknown
- 2006-10-20 HU HUE06807435A patent/HUE026045T2/hu unknown
- 2006-10-20 SI SI200631930T patent/SI1937229T1/sl unknown
- 2006-10-20 RU RU2008120018/15A patent/RU2497507C2/ru not_active Application Discontinuation
- 2006-10-20 WO PCT/EP2006/067619 patent/WO2007045689A2/en not_active Ceased
- 2006-10-20 EP EP06807435.0A patent/EP1937229B1/en active Active
- 2006-10-20 JP JP2008536060A patent/JP5873616B2/ja active Active
-
2015
- 2015-06-10 CY CY20151100506T patent/CY1116503T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1937229T3 (pl) | 2015-08-31 |
| DK1937229T3 (da) | 2015-06-22 |
| ITMI20051999A1 (it) | 2007-04-22 |
| US20080226736A1 (en) | 2008-09-18 |
| EP1937229B1 (en) | 2015-03-11 |
| US9138407B2 (en) | 2015-09-22 |
| SI1937229T1 (sl) | 2015-08-31 |
| JP2009512663A (ja) | 2009-03-26 |
| EP1937229A2 (en) | 2008-07-02 |
| WO2007045689A3 (en) | 2007-09-07 |
| HUE026045T2 (hu) | 2016-05-30 |
| PT1937229E (pt) | 2015-07-16 |
| CY1116503T1 (el) | 2017-03-15 |
| RU2008120018A (ru) | 2009-11-27 |
| WO2007045689A2 (en) | 2007-04-26 |
| RU2497507C2 (ru) | 2013-11-10 |
| JP5873616B2 (ja) | 2016-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2537777T3 (es) | Composiciones farmacéuticas para inhalación en forma de polvos secos, soluciones o suspensiones | |
| CA2115065C (en) | Ultrafine particle powder for inhalation and method for production thereof | |
| ES2670025T3 (es) | Formulación para inhalación líquida que comprende RPL554 | |
| US7625865B2 (en) | Insulin highly respirable microparticles | |
| ES2880271T3 (es) | Polvos pulmonares de ultra baja densidad | |
| ES2525087T3 (es) | Polvos basados en fosfolípidos para administración de fármacos | |
| ES2913095T3 (es) | Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos | |
| US20190022053A1 (en) | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) | |
| Singh et al. | Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution | |
| Elkomy et al. | Innovative pulmonary targeting of terbutaline sulfate-laded novasomes for non-invasive tackling of asthma: statistical optimization and comparative in vitro/in vivo evaluation | |
| JP7277490B2 (ja) | 肺送達用ラパマイシン粉末 | |
| Garcia-Contreras et al. | Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy | |
| CN111991375A (zh) | 一种雾化吸入用瑞德西韦脂质体及其制备方法 | |
| CN111265499B (zh) | 一种洛匹那韦吸入气雾剂及其制备方法 | |
| CN115768404B (zh) | 含乌美溴铵和三苯乙酸维兰特罗的药物制剂 | |
| US20230052424A1 (en) | Peramivir Dry Powder Inhaler and Method of Preparing the Same | |
| ES2918193T3 (es) | Polvo medicamentoso para administración por inhalación y un proceso del mismo | |
| Miyagi et al. | Optimizing adjuvant inhaled chemotherapy: Synergistic enhancement in paclitaxel cytotoxicity by flubendazole nanocrystals in a cycle model approach | |
| Kumar Padhi et al. | Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload | |
| US20210290568A1 (en) | Inhalable formulation of a solution containing levalbuterol tartrate | |
| Taylor et al. | In‐vitro Evaluation of Dry Powder Inhaler Formulations of Micronized and Milled Nedocromil Sodium | |
| US20250352467A1 (en) | Pharmaceutical composition for dry powder inhalation and preparation method thereof | |
| Pawar et al. | Insights of Dry Powder Inhaler: An Emerging Potential Drug Delivery with Novel Therapeutic Carriers | |
| JP2025513460A (ja) | 粉末吸入による医薬品の送達 | |
| US10034857B2 (en) | Triptan powders for pulmonary delivery |